Concord Biotech Limited

BSE: CONCORDBIO543960ISIN INE338H01029

Healthcare
Pharmaceuticals
BSE 500

Share price

₹655.20+40.28 (+6.55%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

4 Nov 2026 · Bonus 1:1

52W high: ₹807.02
52W low: ₹493.52
Off 52W high: -18.81%
1M return: -3.27%
3M return: -5.21%
6M return: +7.14%
1Y return: -10.06%
20D avg volume: 12,577
50 DMA: ₹699.61
200 DMA: ₹633.55

Key ratios Consolidated

Market cap: ₹13,709 Cr
Current price: ₹655.20
52W high / low: ₹807.02 / ₹493.52
Face value: ₹1.00
P/E: 24.53
P/B: —
EPS (TTM): ₹26.71
Book value / share: —
ROE: —
ROCE: 16.60%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-12.19 Cr
Interest cover: 1,221.50
Dividend yield: 1.15%
Dividend / share (TTM): ₹7.55
Payout: 28.27%
Cash conversion cycle: 236.8 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	309.07	257.49	326.08	277.77	247.06	203.99	429.88	244.22	310.18	215.80	318.97	240.80
	10.17	12.83	15.35	9.98	13.35	13.68	9.38	14.73	10.03	10.31	10.81	8.19
	319.24	270.31	341.43	287.74	260.41	217.67	439.27	258.95	320.21	226.11	329.78	248.98
	223.10	193.25	227.18	197.61	177.02	160.43	254.17	159.63	186.91	147.94	198.86	148.90
	63.66	69.85	70.54	66.59	57.30	59.91	80.27	60.96	68.05	55.03	55.67	47.39
	16.24	11.29	15.67	20.45	13.65	12.85	10.32	12.19	21.70	11.78	11.45	23.22
	52.31	43.64	47.77	46.78	44.46	37.90	38.97	34.64	33.66	31.66	33.95	30.67
	0.03	0.04	0.08	0.08	0.06	0.06	0.10	0.10	0.10	0.24	0.46	0.49
	18.38	18.10	19.54	18.75	18.39	17.78	14.62	13.26	13.31	13.18	13.72	13.54
	78.82	77.18	73.96	66.27	65.09	59.59	72.00	—	63.52	54.56	61.88	57.11
	96.14	77.07	114.25	90.13	83.39	57.24	185.09	99.32	133.29	78.17	130.92	100.08
	0.00	0.00	0.00	-3.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	96.14	77.07	114.25	86.85	83.39	57.24	185.09	99.32	133.29	78.17	130.92	100.08
	25.91	20.65	25.61	22.51	22.62	14.67	43.16	25.23	34.59	19.93	33.70	25.53
	69.57	57.70	88.47	63.64	63.06	44.06	140.39	75.92	95.74	59.59	95.02	77.57
	6.65	5.52	8.46	6.08	6.03	4.21	13.42	7.26	9.15	5.70	9.08	7.41
Key metrics
	114.55	95.21	133.87	105.68	101.84	75.08	199.81	112.68	146.70	91.59	145.10	114.11
	37.10%	37.00%	41.10%	38.00%	41.20%	36.80%	46.50%	46.10%	47.30%	42.40%	45.50%	47.40%
	22.50%	22.40%	27.10%	22.90%	25.50%	21.60%	32.70%	31.10%	30.90%	27.60%	29.80%	32.20%
	4.50%	—	5.50%	—	4.50%	—	10.00%	—	—	—	—	—
	25.10%	26.20%	-24.10%	13.70%	-20.30%	-5.50%	34.80%	1.40%	—	—	—	—
	10.30%	31.00%	-37.00%	-16.20%	-34.10%	-26.10%	47.70%	-2.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,170	1,055	1,200	1,017
	48.33	52.36	44.45	33.78
	1,219	1,107	1,245	1,051
	841.14	762.23	748.66	641.53
	270.64	254.35	264.31	184.54
	63.65	62.61	55.99	56.74
	190.50	176.91	138.93	123.05
	0.23	0.28	0.53	2.55
	74.77	74.46	54.37	53.59
	296.23	264.92	249.31	233.14
	377.59	345.01	495.88	409.19
	-3.28	-3.28	0.00	0.00
	374.31	341.74	495.88	409.19
	94.68	85.42	122.91	104.46
	279.38	259.23	371.64	308.10
	26.71	24.78	35.52	29.45
Key metrics
	449.31	416.48	550.78	465.33
	38.39%	39.50%	45.90%	45.80%
	23.87%	24.60%	31.00%	30.30%
	—	16.60%	26.80%	—
	4.02%	-12.10%	18.00%	—
	-13.62%	-30.20%	20.60%	—
	—	171.73	133.35	—
	—	1.03	0.66	—
	—	0.00	0.00	—
	—	-12.19	-0.52	—
	—	236.8	197.2	—
Balance sheet
	—	2,235	2,034	—
	—	1,250	1,135	—
	—	12.19	0.90	—
	—	460.20	521.65	—
	—	326.36	239.67	—
	—	22.68	—	—
	—	785.72	791.80	—
	—	101.91	113.04	—
	—	169.08	184.06	—
	—	0.00	0.38	—
	—	0.00	0.38	—
	—	0.00	0.00	—
	—	2,015	1,813	—
Cash flow
	—	266.88	244.52	—
	—	-142.72	-159.99	—
	—	-112.88	-98.77	—
	—	95.15	111.17	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	312.31	260.52	325.89	278.13	247.06	203.99	429.88	244.22	310.18	215.80	318.97	240.80
	10.45	13.10	15.54	10.08	13.43	13.68	9.38	14.73	10.03	10.31	10.81	8.19
	322.77	273.61	341.43	288.22	260.49	217.67	439.27	258.95	320.21	226.11	329.78	248.98
	220.85	191.40	223.06	194.64	174.97	160.43	254.17	159.63	186.91	147.94	198.86	148.90
	63.66	69.85	70.54	66.59	57.30	59.91	80.27	60.96	68.05	55.03	55.67	47.39
	15.70	11.26	15.67	20.07	13.65	12.85	10.32	12.19	21.70	11.78	11.45	23.22
	49.04	41.18	45.02	44.09	43.18	37.90	38.97	34.64	33.66	31.66	33.96	30.67
	0.01	0.01	0.06	0.06	0.06	0.06	0.10	0.10	0.10	0.24	0.46	0.50
	18.34	18.05	19.49	18.67	18.39	17.78	14.62	13.26	13.31	13.18	13.72	13.54
	77.75	76.52	72.82	65.66	64.32	59.59	72.00	—	63.52	54.56	61.88	57.11
	101.92	82.21	118.38	93.57	85.52	57.24	185.09	99.32	133.29	78.17	130.92	100.08
	0.00	0.00	0.00	-3.28	0.00	0.00	0.00	—	—	—	—	—
	101.92	82.21	118.38	90.30	85.52	57.24	185.09	99.32	133.29	78.17	130.92	100.08
	26.21	21.02	28.36	22.51	22.62	14.67	43.16	25.23	34.59	19.93	33.70	25.53
	75.71	61.19	90.02	67.78	62.90	42.57	141.94	74.09	98.70	58.24	97.21	74.55
	7.24	5.85	8.60	6.48	6.01	4.07	13.57	7.08	9.43	5.57	9.29	7.13
Key metrics
	120.27	100.27	137.93	109.03	103.97	75.08	199.81	112.68	146.70	91.59	145.10	114.12
	38.50%	38.50%	42.30%	39.20%	42.10%	36.80%	46.50%	46.10%	47.30%	42.40%	45.50%	47.40%
	24.20%	23.50%	27.60%	24.40%	25.50%	20.90%	33.00%	30.30%	31.80%	27.00%	30.50%	31.00%
	4.80%	—	5.70%	—	4.60%	—	10.00%	—	—	—	—	—
	26.40%	27.70%	-24.20%	13.90%	-20.30%	-5.50%	34.80%	1.40%	—	—	—	—
	20.40%	43.70%	-36.60%	-8.50%	-36.30%	-26.90%	46.00%	-0.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,177	1,055	1,200	1,017
	49.17	52.73	44.45	33.78
	1,226	1,108	1,245	1,051
	829.95	753.09	748.66	641.53
	270.64	254.35	264.31	184.54
	62.70	62.23	55.99	56.74
	179.33	170.19	138.93	123.05
	0.14	0.23	0.53	2.55
	74.55	74.33	54.37	53.59
	292.75	262.39	249.31	233.14
	396.08	354.71	495.88	409.19
	-3.28	-3.28	0.00	—
	392.81	351.43	495.88	409.19
	98.10	88.17	122.91	104.46
	294.70	263.27	372.96	304.73
	28.17	25.17	35.65	29.13
Key metrics
	467.50	425.99	550.78	465.33
	39.72%	40.40%	45.90%	45.80%
	25.04%	25.00%	31.10%	30.00%
	—	17.00%	26.80%	—
	4.59%	-12.10%	18.00%	—
	-8.34%	-29.40%	22.40%	—
	—	168.74	133.35	—
	—	1.00	0.66	—
	—	0.00	0.00	—
	—	-7.89	-0.52	—
	—	237.0	197.2	—
Balance sheet
	—	2,237	2,034	—
	—	1,245	1,135	—
	—	7.89	0.90	—
	—	460.60	521.65	—
	—	325.69	239.67	—
	—	22.28	—	—
	—	785.63	791.80	—
	—	101.18	113.04	—
	—	167.24	184.06	—
	—	0.00	0.38	—
	—	0.00	0.38	—
	—	0.00	0.00	—
	—	2,020	1,813	—
Cash flow
	—	263.78	244.52	—
	—	-142.28	-159.99	—
	—	-114.51	-98.77	—
	—	95.04	111.17	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +4.59%
Profit YoY (TTM): -8.34%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +4.02%
Profit YoY (TTM): -13.62%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 44.09%

Quarter	September 2026	June 2026
Promoter %	44.09%	44.08%

Holder	Type	Holding	Previous	Change
Sudhir Kumar Vaid	Promoter	28.84%	28.84%	0.00%
Manju Vaid	Promoter Group	9.55%	9.55%	0.00%
Nishtha Jhunjhunwala Discretionary Trust	Public	8.03%	—	—
Aryaman Jhunjhunwala Discretionary Trust	Public	8.03%	8.03%	0.00%
Aryavir Jhunjhunwala Discretionary Trust	Public	8.03%	8.03%	0.00%
Sudman Consultants Llp	Promoter Group	4.54%	4.54%	0.00%
Dsp Small Cap Fund	Public	3.21%	1.75%	+1.46%
Government Pension Fund Global	Public	2.95%	2.95%	0.00%
Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund	Public	2.68%	2.48%	+0.20%
Axis Max Life Insurance Limited Ac Reversionary Bonus Participating Equity	Public	1.33%	—	—
Ravindra Raichand Dharamshi	Public	1.20%	1.20%	0.00%
Chanakya Corporate Services Pvt Ltd	Public	1.11%	1.11%	0.00%
Sbi Healthcare Opportunities Fund	Public	1.06%	—	—
Ankur Sudhir Vaid	Promoter	0.56%	0.56%	0.00%
Vaid Megha Ankur	Promoter Group	0.52%	0.52%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Concord Biotech Limited	13,709	655.20	24.53	16.60%	+4.02% TTM	-13.62% TTM	-10.06%

Filings & corporate actions

Recent announcements

Transcript of Q2 - FY27 Earnings call held on October 28, 20263 Nov 2026 · Company Update / Earnings Call Transcript
Earning Call Recording- For the Second Quarter and half year ended on September 30, 202628 Oct 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.28 Oct 2026 · Company Update / Analyst / Investor Meet
Press release - For the Second quarter and half year ended on September 30, 202628 Oct 2026 · Company Update / Newspaper Publication
Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 202627 Oct 2026 · Company Update / Investor Presentation
The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1.27 Oct 2026 · Corp. Action / Record Date
Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.27 Oct 2026 · Result / Financial Results
The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter ....27 Oct 2026 · Board Meeting / Outcome of Board Meeting
Submission of Scrutinizer''s report and Voting Results of Postal Ballot dated September 23, 202626 Oct 2026 · AGM/EGM / Postal Ballot
Earnings Call Invite for the operational and financial performance of the Company for the Quarter and half year ended on September 30, 202623 Oct 2026 · Company Update / Analyst / Investor Meet
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....22 Oct 2026 · Board Meeting / Board Meeting
In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading ....28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper advertisement for Notice of Postal Ballot dated September 23, 2026 and Remote E-Voting Information25 Sep 2026 · Company Update / Newspaper Publication
Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the Postal Ballot Notice dated September 23, 2026 together with explanatory statement thereto.24 Sep 2026 · AGM/EGM / Postal Ballot
The Board of Director at its meeting held today i.e. Wednesday, September 23, 2026, has inter-alia considered and approved Issuance of Bonus shares & Increase in the Authorised Share Capital ....23 Sep 2026 · Board Meeting / Outcome of Board Meeting
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/09/2026 ,inter alia, to consider and approve the proposal for declaration ....19 Sep 2026 · Board Meeting / Board Meeting
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II - Valthera Formulation Facility of the Company.18 Sep 2026 · Company Update / General
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time ....17 Sep 2026 · Company Update / Analyst / Investor Meet
We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.21 Aug 2026 · Company Update / Analyst / Investor Meet
Transcript of Q1 - FY27 Earnings call held on August 03, 20267 Aug 2026 · Company Update / Earnings Call Transcript
The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3 ....3 Aug 2026 · Company Update / Analyst / Investor Meet
Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 20261 Aug 2026 · Company Update / Investor Presentation
Pursuant to regulation 44(3) of the SEBI (LODR) Regulations, 2015 and section 108 of the Companies Act, 2013, the voting results along with the scrutinizers report for the business items ....1 Aug 2026 · AGM/EGM / AGM
Newspaper publication cutouts of unaudited Standalone and Consolidated Financial results for the first quarter ended June 30, 20261 Aug 2026 · Company Update / Newspaper Publication
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.31 Jul 2026 · AGM/EGM / AGM
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 202631 Jul 2026 · Result / Financial Results
We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, ....31 Jul 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged ....28 Jul 2026 · Company Update / Analyst / Investor Meet
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited Standalone and ....28 Jul 2026 · Board Meeting / Board Meeting
Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting information8 Jul 2026 · Company Update / Newspaper Publication
The register of members and share transfer book of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026. Further the Company has fixed Friday, July 24, 2026 ....7 Jul 2026 · Corp. Action / Record Date
Business Responsibility and Sustainability Report for financial year 2025-267 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year 2025-267 Jul 2026 · Others / Reg. 34 (1) Annual Report
The Notice of 41st Annual General Meeting of the Company of scheduled to be held on Friday, July 31, 2026 through Video Conferencing (VC) / Other Audio-visual means(OAVM) at 12:00 Noon ....7 Jul 2026 · AGM/EGM / AGM
Newspaper advertisement for Notice of 41st Annual General Meeting.6 Jul 2026 · Company Update / Newspaper Publication
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate dated July 01, 2026 issued by MUFG Intime India Private Limited ....6 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s code of conduct for Regulating, Monitoring and Reporting ....27 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation ....25 Jun 2026 · Company Update / General
We are pleased to announce that the Company has entered into an agreement to Invest in M/s. FSGE Renewable Power Private Limited for installation of Wind Solar Hybrid Power Project having ....20 Jun 2026 · Company Update / Acquisition

Corporate actions

Purpose	Ex date	Record date	Payment date
Bonus issue 1:1	4 Nov 2026	4 Nov 2026	—
Final Dividend - Rs. - 7.5500	24 Jul 2026	24 Jul 2026	—
Final Dividend - Rs. - 10.7000	3 Sep 2025	3 Sep 2025	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
31 Jul 2026 Board Meeting - Financial Results